TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33875611
Drug: PVSRIPO monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVSRIPO monotherapy (1, 2, or 3 injections with 21 days between injections)
Study: 33875845
Drug: Intravenous olipudase
Normalized name: olipudase alfa
DrugBank: Olipudase alfa (DB12835)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous olipudase alfa administered every 2 weeks with intrapatient dose escalation to 3 mg/kg
Study: 33876222
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and intravenous iron tracers administered before treatment and after intensive phase (8/12 weeks) and complete treatment (24 weeks)
Study: 33876229
Drug: Maternal antimicrobial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal antimicrobial treatment ≥1 day before delivery
Study: 33876229
Drug: No maternal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No maternal antimicrobial treatment
Study: 33876576
Drug: Pamiparib 60
Normalized name: Pamiparib
DrugBank: Pamiparib (DB14769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamiparib 60 mg orally twice daily
Study: 33877496
Drug: Football training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Football training (twice weekly for six months)
Study: 38532458
Drug: Belumosudil 200
Normalized name: belumosudil 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belumosudil 200 mg once daily
Study: 33877856
Drug: Belumosudil 400
Normalized name: BELUMOSUDIL
DrugBank: Belumosudil (DB16703)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Belumosudil 400 mg once daily
Study: 33877856
Drug: Corticosteroid (CS)
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid (CS) treatment
Study: 33878776
Drug: Uterus transplantation
Normalized name: Oryctolagus cuniculus uterus preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uterus transplantation with immunosuppressive therapy
Study: 33879263
Drug: Azithromycin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (single directly observed dose)
Study: 33879458
Drug: IMU-131 (B-cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMU-131 (B-cell epitope vaccine)
Study: 33879458
Drug: C3 cohort
Approvals — FDA: no, EMA: no, PMDA: no
Description: C3 cohort (50 μg dose)
Study: 33879458
Drug: C1 and
Normalized name: C1-INH
DrugBank: Human C1-esterase inhibitor (DB06404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: C1 and C2 cohorts (10 and 30 μg doses)
Study: 33879515
Drug: Insulin-induced blood
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-induced blood glucose normalization (from 7.6±0.4 mmol/L to 4.5±0.07 mmol/L for 1 hour)
Study: 33879515
Drug: Insulin-induced blood
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-induced blood glucose normalization
Study: 33879515
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group maintained at 4.9±0.1 mmol/L
Study: 33879601
Drug: pembrolizumab 2
Normalized name: pembrolizumab 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: pembrolizumab 2 mg/kg every 3 weeks for ≤2 years
Study: 33879601
Drug: salvage therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: salvage therapies including chemotherapies and immunotherapies
Study: 33879722
Drug: Aggressive hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive hydration with Lactated Ringer Solution
Study: 33880438
Drug: Intensive Therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive Therapy Unit (ITU) workers
Study: 33880555
Drug: Nivolumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab plus ipilimumab (1 mg/kg and 3 mg/kg respectively, intravenously every 3 weeks ×4, followed by nivolumab 3 mg/kg every 2 weeks until progression, unacceptable toxicity, or 24 months)
Study: 33880939
Drug: Sufentanil sublingual
Normalized name: SUFentanil Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil sublingual tablet analgesia
Study: 33881209
Drug: Prexasertib (LY2606368)
Normalized name: Prexasertib
DrugBank: Prexasertib (DB12008)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prexasertib (LY2606368) administered intravenously on days 1 and 15 of a 28-day cycle at dose levels of 80, 100, 125, and 150 mg/m²
Study: 33881718
Drug: Qishe Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qishe Pill (3-4 g/kg for 4 weeks)
Study: 33882147
Drug: Mycophenolic acid
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mycophenolic acid (MPA) use (adjusted for prior MPA discontinuation)
Study: 33882846
Drug: Rilonacept (IL-1α/IL-1β
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilonacept (IL-1α/IL-1β cytokine trap) administered weekly during a 6-week base treatment period plus an optional 18-week extension period.
Study: 33885369
Drug: Digital health
Normalized name: MENS HEALTH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital health intervention (DHI) using animated health videos and InfoSpots; exposure to 3 different health animations once on a tablet device.
Study: 33888901
Drug: Belzutifan (MK-6482)
Normalized name: belzutifan
DrugBank: Belzutifan (DB15463)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Belzutifan (MK-6482) administered orally at 120 mg once daily in patients with ccRCC (n=55)
Study: 33888901
Drug: Belzutifan (MK-6482)
Normalized name: belzutifan
DrugBank: Belzutifan (DB15463)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Belzutifan (MK-6482) administered orally at various doses in dose-escalation cohort (n=43)
Study: 33888901
Drug: Belzutifan (MK-6482)
Normalized name: belzutifan
DrugBank: Belzutifan (DB15463)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Belzutifan (MK-6482) administered orally at various doses
Study: 33891621
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care EoE treatment for 2 months
Study: 33892111
Drug: Extended-release methylphenidate
Normalized name: methylphenidate Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release methylphenidate (MPH-MLR)
Study: 33892407
Drug: Nivolumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (3 mg/kg every 2 weeks) + Metronomic cyclophosphamide (25 mg/m2)
Study: 33893210
Drug: HIV positive
Normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV positive subjects receiving antiviral treatment (32%)
Study: 33893210
Drug: HIV negative
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV negative subjects receiving antiviral treatment (6%)
Study: 33893289
Drug: Fulvestrant treatment
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant treatment
Study: 33893692
Drug: Durvalumab (1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (1,500 mg every 4 weeks × 13) and Tremelimumab (75 mg Q4 weeks × 7, then Q12 weeks × 2)
Study: 33895695
Drug: Exposure to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure to newly released anti-HER2 therapies (e.g. pertuzumab) from 2016 onwards
Study: 33895874
Drug: Oral paromomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral paromomycin and metronidazole
Study: 33897579
Drug: Virtual Reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual Reality intervention for motor and cognitive rehabilitation, details on dosage and duration not available.
Study: 33898065
Drug: Oral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulant agents (OACs), including vitamin K antagonists (VKAs) and direct OACs (DOACs)
Study: 33898065
Drug: Oral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulant agents (OACs)
Study: 33898953
Drug: 3-monthly intramuscular
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 3-monthly intramuscular depot medroxyprogesterone acetate (DMPA-IM)
Study: 33898953
Drug: levonorgestrel (LNG)
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: levonorgestrel (LNG) implant
Study: 33900278
Drug: Angiopoietin-like protein
Normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiopoietin-like protein 3 inhibitors
Study: 33901280
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of hyperthyroidism (restoration of euthyroidism)
Study: 33901551
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at clinically administered doses using the Total Intravenous Anesthesia (TIVA/TCI) technique
Study: 33902087
Drug: Adjunctive music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive music during ketamine infusion
Study: 33902087
Drug: Ketamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine infusion without music
Study: 33902320
Drug: Acute Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute Daily Stress
Study: 33902320
Drug: Daily Food
Normalized name: food
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Food Consumption
Study: 33903148
Drug: Pemafibrate (PPARα
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemafibrate (PPARα agonist)
Study: 33903179
Drug: Intravenous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous recombinant tissue plasminogen activator (r-tPA), median dose 0.88 (IQR 0.78-0.90) mg/kg
Study: 33903179
Drug: Urokinase (UK),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urokinase (UK), median dose 1.71 (1.43-2.00)×10
Study: 33904819
Drug: Community-based computerized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based computerized cognitive training (CCT) program, 10-week duration, 2-hour instructor-led group classes twice a week.
Study: 33904821
Drug: Self-reported computerized
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported computerized history taking (CHT) on a tablet
Study: 33905540
Drug: Drug therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapies that reduce gastric acidity
Study: 37523175
Drug: Insulin-Only iLet
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-Only iLet Bionic Pancreas
Study: 33907136
Drug: Self-acupressure therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-acupressure therapy at acupoints TE17 (Yifeng), TE21 (Ermen), SI19 (Tinggong), and GB2 (Tinghui)
Study: 33908631
Drug: Corticosteroids and
Normalized name: Corticosteroids and mydriatics in combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids and antibiotics
Study: 33909232
Drug: Selinexor 60
Normalized name: selinexor 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selinexor 60 mg once weekly in combination with intravenous topotecan
Study: 33909232
Drug: Selinexor 80
Normalized name: SELINEXOR 80MG WEEKLY PKT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selinexor 80 mg
Study: 35911702
Drug: Treatment-related adverse
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-related adverse events (TRAE)
Study: 33909934
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (real-world cohort)
Study: 33910154
Drug: Larger right
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Larger right than left frontal alpha power prior to drug treatment in female patients.
Study: 33910334
Drug: Immunosuppressive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive therapy plus eltrombopag
Study: 33910334
Drug: Immunosuppressive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive therapy alone
Study: 33910334
Drug: Immunosuppressive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive therapy with or without eltrombopag
Study: 33912461
Drug: Apatinib (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib (250 mg orally per day) plus Camrelizumab (200 mg intravenously every three weeks)
Study: 33912470
Drug: Sequential consolidation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential consolidation with pembrolizumab for four cycles followed by nab-paclitaxel for four cycles (P→A)
Study: 33912470
Drug: Concurrent nab-paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Concurrent nab-paclitaxel and pembrolizumab for four cycles (AP)
Study: 33912470
Drug: Quality of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quality of life measured by FACT-L
Study: 33912799
Drug: escitalopram+golimumab (TNF-α
Approvals — FDA: no, EMA: no, PMDA: no
Description: escitalopram+golimumab (TNF-α inhibitor)
Study: 33912799
Drug: escitalopram+calcium tablet+vitamin
Normalized name: escitalopram Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: escitalopram+calcium tablet+vitamin D (PKC activator)
Study: 33912999
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of oxaliplatin
Study: 33913086
Drug: Placebo switched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo switched to upadacitinib 15 mg once daily at week 24
Study: 33913086
Drug: Placebo switched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo switched to upadacitinib 30 mg once daily at week 24
Study: 33913104
Drug: ACV lip
Normalized name: ACV tripeptide
DrugBank: ACV tripeptide (DB02025)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACV lip patch
Study: 33913104
Drug: Placebo lip
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo lip patch
Study: 33914097
Drug: Selinexor 100
Normalized name: selinexor 100 mg/week (20 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selinexor 100 mg weekly with FLAG-Ida
Study: 33914097
Drug: Selinexor (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selinexor (60 mg, 80 mg, 100 mg weekly) with FLAG-Ida
Study: 33914706
Drug: IFN-γ treatment
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-γ treatment
Study: 35430299
Drug: anti-PD-1 therapy
Normalized name: Dianeal PD-2/1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-PD-1 therapy
Study: 33917922
Drug: Antiplatelet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet therapy de-escalation (ticagrelor replaced with clopidogrel)
Study: 33919763
Drug: Novel Oral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel Oral Liquid Formulation of 13-
Study: 33920489
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma (CP) infusion
Study: 33921051
Drug: Single bronchodilation
Normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single bronchodilation monotherapy
Study: 33921166
Drug: Probiotic formulation
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic formulation
Study: 33921867
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K antagonist (VKA) and Rivaroxaban
Study: 33922654
Drug: Oral creatine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral creatine monohydrate (Cr) at a dose of 2 × 7 g per day for 2 months in conjunction with ongoing therapies
Study: 33922654
Drug: Oral creatine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral creatine monohydrate (Cr) at a dose of 2 × 3-5 g per day for 3-6 months (proposed future study)
Study: 33922654
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation as monotherapy or in conjunction with metformin (future potential use)
Study: 33925513
Drug: Accelerometer-measured daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerometer-measured daily step counts (mean 10699.8 steps)
Study: 33925513
Drug: Accelerometer-measured daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerometer-measured daily step counts
Study: 33926412
Drug: Weight-management camp
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-management camp followed by a community intervention (10-week program of weekly lifestyle education and physical activity sessions)
Study: 33926503
Drug: Treatment indicated
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment indicated (surgery or targeted systemic therapy)
Study: 33926797
Drug: Carbon nanoparticles
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbon nanoparticles (CNs) injection (0.3 mL) into the fusion node prior to NAC.
Study: 33926914
Drug: MORAb-202 (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: MORAb-202 (0.3 to 1.2 mg/kg intravenously once every three weeks)
Study: 33927586
Drug: Mobile chat-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile chat-based support plus nicotine replacement therapy sampling (NRT-S)
Study: 33929394
Drug: Anti-PD-1 Inhibitor
Normalized name: anti-inhibitor coagulant complex 1 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-1 Inhibitor
Study: 33929874
Drug: BKV-specific cytotoxic
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BKV-specific cytotoxic T lymphocytes (CTLs) infusion
Study: 39186707
Drug: Sacituzumab govitecan
Normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sacituzumab govitecan (SG) 10 mg/kg on days 1 and 8 of 21-day cycles
Study: 33930223
Drug: Single-tablet combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-tablet combination of sofosbuvir (400 mg) and daclatasvir (30, 60, or 90 mg) for 12 or 24 weeks
Study: 33931857
Drug: Bitopertin, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bitopertin, a glycine transport inhibitor, administered orally, dosage and duration not available.
Study: 33931953
Drug: Clinical inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical inhibitors of BCRP
Study: 33932223
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec (± prandial insulin)
Study: 33932223
Drug: Other basal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other basal insulins (± prandial insulin)
Study: 33933689
Drug: Cognitive Orientation
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Orientation to Daily Occupational Performance (CO-OP) intervention, 14 individual sessions
Study: 33933719
Drug: First-episode antipsychotic-naïve
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-episode antipsychotic-naïve patients with schizophrenia
Study: 33933719
Drug: First-episode antipsychotic-naïve
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-episode antipsychotic-naïve patients with schizophrenia and Healthy controls
Study: 33933925
Drug: Conventional fractionated
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional fractionated radiation therapy (CFRT)
Study: 33933925
Drug: Postmastectomy hypofractionated
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postmastectomy hypofractionated radiation therapy (HFRT)
Study: 33934110
Drug: Pittsburgh Compound-B
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pittsburgh Compound-B (PiB) imaging
Study: 33934351
Drug: MIV-mono (mivebresib
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIV-mono (mivebresib at doses of 1.5, 2.0, or 2.5 mg)
Study: 33934351
Drug: MIV-Ven (mivebresib
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIV-Ven (mivebresib in combination with venetoclax at doses of 400 or 800 mg)
Study: 33936110
Drug: Elevated TNFα
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Elevated TNFα (median (IQR): 8.2 (6.4-9.8) pg/ml)
Study: 33936110
Drug: Elevated IL-1β
Normalized name: IL-1 TRAP
DrugBank: Rilonacept (DB06372)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Elevated IL-1β (0.21 (0.1-0.4) pg/ml)
Study: 33937527
Drug: Gonadotropin-Releasing Hormone
Normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gonadotropin-Releasing Hormone Agonists
Study: 33937611
Drug: Self-efficacy intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-efficacy intervention for coping with breast cancer treatment
Study: 33937624
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of somatic mutations of estrogen receptor alpha
Study: 33937953
Drug: Lorlatinib 100
Normalized name: lorlatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorlatinib 100 mg co-administered with modafinil 400 mg/day
Study: 33937953
Drug: Lorlatinib 100
Normalized name: lorlatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorlatinib 100 mg alone
Study: 33937954
Drug: Lorlatinib (10-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorlatinib (10-200 mg orally once daily and twice-daily doses of 35, 75, and 100 mg in continuous 21-day cycles for phase I; 100 mg once daily in continuous 21-day cycles for phase II)
Study: 33939006
Drug: Narrow diameter
Normalized name: narrowleaf marshelder pollen extract
DrugBank: Iva angustifolia pollen (DB10968)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrow diameter implants in T2DM patients (HbA1C > 6.5%)
Study: 33939006
Drug: Narrow diameter
Normalized name: narrowleaf marshelder pollen extract
DrugBank: Iva angustifolia pollen (DB10968)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrow diameter implants in normo-glycemic patients (HbA1C < 6.0%)